IMIDs affect large populations across the globe, are chronic and costly conditions, and affect patients in the prime of their lives.
They constitute a broad class of diseases, including inflammatory bowel disease, multiple sclerosis, psoriatic arthritis, rheumatoid arthritis, psoriasis, and systemic lupus erythematosus, in which dysregulation of the immune response leads to inflammatory pathophysiology and ultimately tissue destruction.
The collaboration will give Gossamer's world-class immunology research and development team the ability to benefit from IMIDomics' unique clinical and molecular patient database to ultimately inform product discovery and development strategy.
The agreement allows Gossamer to select and collaborate with IMIDomics on multiple projects, the first project being in the field of inflammatory bowel disease.
IMIDomics provides critical insights for treating patients with Immune-Mediated Inflammatory Diseases (IMIDs).
IMIDomics' comprehensive platform integrates access to a dynamic and high quality IMID patient biobank, corresponding curated clinical data, associated proprietary multiomics molecular data and world-class clinical expertise.
The company's analytics platform extracts unique insights into disease biology and patient conditions through our proprietary interactive portal. IMIDomics' unique capabilities result in novel insights that drive drug discovery and development, and guide precision treatment of patients.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca